May. 27 at 1:37 PM
$DTIL $BEAM $CRSP $BMRN $CURE So for Gene Therapy companies, this is a breakthrough and yet another validation: "There has never been a treatment that could directly target and eliminate the root source of hepatitis B viral replication and now there is. "
$DTIL announces this huge news and as of the market open it's not even visible on Yahoo Finance.
-> Data was presented by was presented by Man Fung Yuen MD, Ph.D., Chair Professor of The University of Hong Kong and Li Shu Fan Medical Foundation Professor in Medicine, and the Chief of the Division of Gastroenterology and Hepatology, Queen Mary Hospital, Hong Kong.
He is one of the top internationally renowned researchers in the field of hepatitis B disease. He has now published more than 630 papers in world-renowned medical journals including New England Journal of Medicine, Lancet, Nature Medicine, Lancet Infectious Diseases and Lancet Oncology. He has delivered more than 360 lectures all over the world.
